Tracey Dunn portrait

Written by Tracey Dunn

Tracey Dunn is the Education and AllergyWise® Manager for Anaphylaxis UK. Tracey joined the team following her retirement from Headship having taught and led schools for 30 years. Tracey works with a number of different organisations to ensure the safety of students with allergies. These include the Department of Education and co-chairing the education group of the National Allergy Strategy.

Thankfully, fatal anaphylaxis is rare, but, when it does occur, the consequences are devastating. Helen and Peter Blythe have been tirelessly campaigning for change following the tragic death of their five-year-old son Benedict, who died at school in December 2021 after experiencing anaphylaxis. Their efforts have highlighted critical gaps in how schools protect children with allergies.

Although statutory guidance titled Supporting Pupils with Medical Conditions in School exists, it has not been updated since 2017. During the inquest into Benedict’s death, the Department for Education (DfE) acknowledged these shortcomings and announced it would undertake a review and update of the guidance. Research conducted by the Benedict Blythe Foundation into schools’ ability to respond to allergic emergencies found significant cause for concern. Despite schools being permitted to hold spare adrenaline auto-injectors (AAIs) since 2017, only a small proportion had done so. Combined with inconsistent training and a lack of clear allergy policies, this left children with allergies vulnerable and potentially at risk. These findings are echoed by enquiries to Anaphylaxis UK support helpline, where parents frequently seek clarification about schools’ responsibilities to ensure their children are safe, supported, and included.

In response, the Benedict Blythe Foundation has been campaigning for the introduction of “Benedict’s Law” to ensure that pupils with allergies attend schools that are properly equipped to safeguard them. Benedict’s Law has three mandatory components: training for all school staff, a comprehensive allergy policy, and the availability of spare adrenaline auto-injectors in every school.

In February 2026, significant progress was made. In the same week that leading allergy organisations—including Anaphylaxis UK, Allergy UK, the British Society for Allergy and Clinical Immunology (BSACI), the Benedict Blythe Foundation, and National Allergy Strategy leads—met with Olivia Bailey, Minister for Early Education, to contribute to the review of the statutory guidance, an amendment to the Children’s Wellbeing and Schools Bill was passed by the House of Lords. This amendment confirmed that Benedict’s Law will be implemented in schools from September 2026 as part of the updated guidance.

This represents a historic step forward for children and young people with allergies. It will ensure they can learn in environments that are inclusive and safe, and that staff are properly trained to recognise and respond to allergic reactions and anaphylaxis without delay. Schools will be required to have the necessary medication on site, and staff will be empowered to act confidently and decisively in an emergency.

The updated guidance will be published for consultation by the DfE shortly. The National Allergy Strategy, the Benedict Blythe Foundation, and patient charities including Anaphylaxis UK will work closely with the DfE to provide schools with model policies and practical templates to support compliance with the new statutory requirements.

Schools are welcome to take action now to get ahead of the September 2026 requirements. By undertaking a whole-school allergy risk assessment, arranging staff training and subscribing to the education newsletter, schools can ensure they are fully prepared and compliant before the deadline. Early action will help to protect vulnerable pupils, demonstrate proactivity and give staff confidence in managing allergic emergencies.

Anaphylaxis UK has provided free or low-cost allergy and anaphylaxis training for over a decade, offering both e-learning and face-to-face options alongside a comprehensive suite of resources. Training is continually updated to reflect the latest clinical guidance, including the recent introduction of nasal adrenaline.

Please contact us at Anaphylaxis UK: allergywise@anaphylaxis.org.uk.

Privacy Preference Center